12 helices (Fig. 3) . The antiparallel α-helical fold, comprising a central core layer of three helices (H5/6, H9, and H10), is sandwiched between two additional layers of helices (H1-4 and H7, H8, and H11). This helical arrangement creates a scaffold that maintains a ligand-binding cavity. The remaining secondary structural elements, a small two-stranded antiparallel β-sheet and the dynamically mobile H12, 28, 29 flank the main ERα ERβ three-layered motif. 26, 27 The overall structure of the LBD of ERβ shows a close similarity to that of ERα. 30 Both ERs also contain a relatively unstructured carboxyl-terminal extension, or F domain. The secondary structure of the ERα-F domain appears to contain an α-helical region and an extended β-strand separated by regions of random coil, with a short extended region near the extreme carboxyl-terminus. 31 On the other hand, the F domain of ERβ exhibits a random coil, with only a very short extended region near the extreme carboxyl-terminus of the protein. 31 Although the role of ERβ-F is unclear, the F domain of ERα appears to modulate the transcriptional activity, co-activator interactions, dimerization, and stability of the receptor. [32] [33] [34] Dimer formation is essential for ERα function, as mutations that interfere with dimerization render the receptor transcriptionally inactive. 35 Although the DBD of each monomer also contributes to the dimerization of ERα, the predominant dimerization interface is formed by the H11 helices of each ERα-LBD monomer. 26, 27, 36 The
LBDs interact via a stretch of conserved hydrophobic residue at their amino-terminal ends, with additional dimer interactions provided by the residues of H8 and the loop between H9 and H10. 26, 27 Ligand recognition is achieved through hydrogen bonds and the complementarity of the hydrophobic residues that line the cavity to the non-polar nature of the ER ligands. 26, 27, 37 It appears that E2 binding positions the dynamically mobile H12 over the cavity perpendicular to the dimerization interface and is packed against H3, H5/6, and H11, forming a lid on the binding cavity (Fig. 3) . [26] [27] [28] [29] This positioning of H12 is a prerequisite for transcriptional activation as it generates a competent ligand-dependent activation function (AF)-2 that is capable of interacting with the co-activators. 26, 27, 37 In this conformation, the E2-bound F I G U R E 2 Schematic representation of the estrogen receptor (ER) isoforms. The ERs are encoded by eight exons. The exon boundaries (lines) correspond to the regions of the ERs that are depicted with colored and labeled (A-F) structural domains. Estrogen receptor α is 595 amino acids long, whereas ERβ is composed of 530 amino acids. Estrogen receptor α46, which is generated by an alternative splicing event, lacks the aminoterminal A/B region and acts as a competitive inhibitor of ERα. Estrogen receptor α36 is generated from a promoter in the first intron of the ERα gene, together with alternative splicing events that result in a truncated protein with a unique 27 amino-acid carboxyl-terminus (light blue) that replaces the last 138 amino acids that are encoded by exons 7 and 8 of wild-type (WT)-ERα. Estrogen receptor α36 lacks both activation function (AF)1 and AF-2. Palmitoylated ERα36 localizes to the plasma membrane and cytoplasm, plays a role in the membrane-initiated 17β-estradiol (E2) signaling and adversely affects WT-ERα-mediated events. The ERβ isoforms are formed from alternative splicing of exon 8, resulting in carboxyl-terminally truncated ERβ2, ERβ4, and ERβ5 variants with varying molecular masses. These variants cannot bind ligand and lack AF-2, but they could adversely affect E2 signaling by heterodimerizing with WT-ERα or WT-ERβ when co-synthesized ). The binding of 4-HT, a selective estrogen receptor modulator, prevents H12 from docking in agonist conformation, effectively preventing co-activator binding and transcription activation (PDB ID: 3ERT; Shiau, et al. 38 ). H12 and the residues at the amino and carboxyl-termini of the tertiary structures are indicated for comparison
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LBD can accept a short helical segment, the LXXLL motif (where "L" is leucine and "X" is any residue) from a variety of co-activator proteins, which is exemplified by the members of the p160 steroid receptor coactivator (SRC) family, including SRC1-3. 25, 38, 39 Estrogen receptors also bind to various molecules with agonist, mixed agonist-antagonist, or full antagonist properties. 40 In other NHRs, antagonist binding locates H12 to a position outside the AF-2 region, leading to an interaction with the corepressor/nuclear receptor (CoRNR) consensus motif (LIL; where "L" is leucine, "I" is isoleucine, and "X" is any residue) of the corepressor proteins. 44 Unlike most NHRs, however, the importance of NR corepressors in ER signaling remains unclear. Nevertheless, studies have indicated that both agonist-and antagonist-bound ERs are able to recruit a variety of proteins that can repress receptor activity. 45 A search for a mechanism identified a previously unrecognized internal CoRNR motif within H12. 46 This motif is able to compete with corepressors to bind to the AF-2 surface, thereby reducing or preventing the ability of ERα to directly interact with the corepressors. This suggests that corepressor proteins might not require CoRNR motifs for recruitment to the antagonistbound ERα. 46 Furthermore, dynamic modeling of tamoxifen-occupied ERα suggests that, in the presence of tamoxifen, the ERα-LBD assumes flexible conformations that fluctuate between agonist and antagonist confirmation. 47 These fluctuating conformations could underlie the mixed agonist-antagonist property of the compound. 47 In addition to blocking ER-cofactor interactions, 48 fulvestrant (as an effective SERD) prevents the binding of ERα to DNA by altering the stability, turnover, and intra-nuclear location of the receptor. [49] [50] [51] [52] [53] Although the structural features of the LBDs of ERα and ERβ largely overlap, the ligand-binding pocket of ERβ differs from that of ERα, with only two amino-acid positions. This, together with distinct residues outside of the LBD, generates differences in the size of the pockets that allow the binding of a ligand to receptors in a subtype-specific manner, exemplified by ERβ-specific agonist diarylpropionitrile. 54 Studies using subtype-selective agonists and antagonists have been critical in determining the biological actions that are specific to ERα or ERβ, extending the findings from ER-KO animal models.
| Structure of the estrogen receptor-DNAbinding domain
The nuclear ERs interact with chromatin target sites through two distinct modes: estrogen response element (ERE)-dependent and ERE-independent pathways. The EREs are permutations of the 5′-GGTCAnnnTGACC-3′ DNA palindrome, wherein 'n' denotes a nonspecific three-nucleotide spacer, located at various distances from the transcription start site and/or within a gene locus. 20, 55 The regulation of gene expression by the binding of E2-ER to the EREs is referred to as the "ER-dependent signaling pathway." 19, [56] [57] [58] [59] [60] On the other hand, the transcriptional modulation of target genes through the interactions of E2-ERα with transcription factors, exemplified by stimulatory protein (SP) 1 and activator protein (AP) 1, bound to their cognate regulatory elements on DNA, denotes the ERE-independent signaling pathway. [57] [58] [59] [60] The underlying mechanism of the ERE-independent signaling pathway is unclear. However, the ER has been suggested to establish direct or indirect, via co-regulatory proteins, interactions with transcription factors through regions that also encompass the DBD, while the integrated effects of the amino-and carboxyl-termini are responsible for the regulation of transcription. 19, [56] [57] [58] [59] [60] The DBDs mediate the ability of ERs to bind to EREs. The centrally positioned DBDs, which are highly conserved among NHRs, 28 share the same three-dimensional structure (Fig. 4) . The DBD of ERα contains two zinc-binding motifs and each motif contains an α-helix that is nucleated at its amino-terminus through binding a zinc ion. 61 Two helices are oriented perpendicularly to each other and cross at their midpoints. 61 The DBD makes phosphate contacts on both sides of the major groove. 61 Each DBD of the ERα dimer makes analogous contacts with one of the inverted motifs, resulting in a rotationally symmetrical structure. 61 Two monomers of the DBD bind to adjacent major grooves from one side of the DNA double helix. Distinct residues in a region of the first zinc-finger module of DBD, the P-box, particularly Glu203, Gly204, and Ala207, determine the DNA-binding specificity that is critical for sequence discrimination 12, 62, 63 and binding to the ERE. 64 The residues in the second zinc finger-like module, the D-box, are involved in the discrimination of half-site spacing through a protein-protein interaction between two ER monomers.
12,62,63
| Structure of the estrogen receptor amino-terminus
The highly divergent amino-terminal domain of many members of the NHR family contains an AF-1 region. 65 that the functional integration of both AF-1 and AF-2 is required for the full activity of the receptor. [69] [70] [71] [72] These results have been confirmed by the findings derived from mouse KI models. 42, 43 Despite the important functions of the amino-terminus in ER activity, the biochemical and structural features of the underlying mechanism of AF-1 action are incomplete. This is because the amino-termini of NHRs, including ERα, are intrinsically disordered. 65, [73] [74] [75] It has been proposed that this intrinsic disorder leads to the formation of a large collection of rapidly inter-converting receptor conformations. 65, [73] [74] [75] An intrinsic disorder allows the amino-terminus to rapidly and reversibly adopt various configurations. These conformational changes are controlled by allosteric cooperativity between different domains and interactions with proteins and post-translational modifications, particularly phosphorylation. 76 For example, the TATA box-binding protein was shown to interact with and induce a more ordered structure in the amino-terminus of ERα. 75 Similarly, the phosphorylation of serine 118
in the amino-terminus of ERα that was bound to E2 or SERM (tamoxifen) by growth factor signaling resulted in the recruitment of the peptidyl prolyl cis/trans isomerase, Pin1, that isomerizes the serine 118-proline 119 bond from a cis to a trans isomer. This isomerization appears to lead to a local conformational change that promotes the ligand-independent and agonist-or SERM-inducible activity of ERα. 76 These protein interaction-mediated conformational changes are critical for stable interactions with other co-regulatory proteins in order to establish an effective transcription. 65, 73, 74 In contrast to ERα, the amino-terminus of ERβ impairs the receptor ERE interactions, 77 does not contain an AF-1, 19, 72, [78] [79] [80] and does not interact with the carboxyl-terminus. 72 
| 17Β-ESTRADIOL-ESTROGEN RECEPTOR SIGNALING
A Nevertheless, a dissected review of the relative contribution of these compartmentalized ER locations to E2 signaling is a necessary prelude in order to provide a current short story of the mechanism of ER actions at various levels, for which there exist excellent reviews. which results in the activation of Gα and Gβγ proteins in a cell-type dependent manner. 99, 100 This leads to rapid E2 signaling. [94] [95] [96] [97] [98] The E2-dependent depalmitoylation of, at least, ERα decreases receptorcaveolin-1 association. This allows ER redistribution and its association with adaptors and/or signaling proteins, including the proline-, glutamic acid-, and leucine-rich protein 1, modulator of non-genomic activity of ERs (PELP1/MNAR), tyrosine kinase src, and tyrosine kinase receptors. 94, [100] [101] [102] This, in turn, contributes to the activation of the ERK/MAPK and PI3K/AKT signaling cascades, impacting cellular proliferation, migration, and many other processes.
100-102
Despite the well-established protective role of E2 in the cardiovascular system, the mechanism by which E2 mediates its effect has been largely unclear. Recent studies have used a novel selective ER modulator, termed the "estrogen dendrimer conjugate," or EDC, 103 in a mouse model. The findings revealed that the membrane-initiated ER signaling regulates processes that could be central to cardiovascular health and disease. 99 The EDC, which possesses a minimal capacity to induce genomic activities because of its size and charge, stimulates endothelial cells, but not other cell types, and their proliferation and migration by inducing ERα-G protein interaction. 99 This interaction leads to the activation of endothelial nitric oxide synthase and nitric oxide production. 99 The development of mouse models that synthesize the ligandbinding domain (E) of ERα in order to target the domain exclusively to the cell membrane 104 or the mutation of the Cys451 residue to Ala 105, 106 in order to prevent palmitoylation, and hence the trafficking of the receptor to the membrane, are supportive of E2-mediated membrane signaling. Disjointing the nuclear ER-mediated transcriptional events, these in vivo models display infertility, abnormal ovaries, abnormal pituitary hormone regulation, stunted mammary gland ductal development, and altered vascular events. 105, 106 Importantly, the cells that were isolated from the affected organs or tissues of these mice showed profoundly affected membrane signaling in response to E2.
105,106
| Estrogen receptor-mediated mitochondrial events
The mitochondria are essential for adenosine triphosphate (ATP) production, heme biosynthesis, β-oxidation, the metabolism of certain
In the membrane-initiated signaling, the E2-bound and palmitoylated (green) ER interacts with a G protein (GP) that results in the activation of kinases, which in turn phosphorylate substrates, including membrane-based ion channels and secondary messenger systems, leading to rapid cellular responses. The activated kinases also phosphorylate the protein components of the nuclear E2 signaling, including ERs, co-regulatory proteins, transcription factors (TFs), and chromatin proteins, that result in alterations in responsive gene expression. In the mitochondria, E2-ER alters the mitochondrial functions by mediating gene expression through a direct interaction with the mtDNA, as well as increasing manganese superoxide dismutase. The mitochondrial functions also are modulated by the nuclear E2-ERs through the expression of genes, whose protein products are involved in mitochondrial functions. In the nuclear signaling, the ER mediates E2 action with two distinct modes: estrogen response element (ERE)-dependent and ERE-independent pathways. The ERE-dependent signaling route involves the interactions of E2-ER with EREs on DNA and the subsequent regulation of gene expression. The ERE-independent signaling pathway entails the modulation of responsive gene expression by a direct or indirect, through co-regulatory proteins (CRs), interaction of E2-ER with transcription factors that are bound to their cognate responsive elements on DNA 
Mitochondria
Nucleus amino acids, and steroid synthesis. 84 The mitochondria also are involved in the control and mediation of apoptosis that is induced by several stimuli, including those that increase reactive oxygen species (ROS). 84 Accumulating evidence suggests that the mitochondria are im- 23 Derived from the same genes encoding nuclear ERs, 23 the presence of ERs in the mitochondria in the cells of various tissues suggests that mitochondrial ERs could directly mediate the effects of E2 within the mitochondria. However, the mechanism by which ERs are translocated into the mitochondria is unclear. The nuclear-encoded mitochondrial proteins contain signal sequences that target them to the mitochondria through chaperone proteins. 109, 110 The translocation of some mitochondrial proteins also occurs co-translationally, such that mitochondrial proteins that are synthesized on cytosolic ribosomes are imported to the organelle. 109, 110 Although ERs lack a sequence that targets them to the mitochondria, co-translational translocation of ERs is a plausible mechanism for mitochondrial residency of the receptors.
Mitochondrial DNA (mtDNA) is a 16.5 kb circular genome that encodes 13 mRNAs, two rRNAs, and 22 tRNAs. of breast and lung carcinomas. 114 Based on these observations, it was suggested that, in addition to the transcriptional regulation of some of the mitochondrial genes through nuclear E2-ER signaling, the protein products of NRF-1-regulated genes enter into the mitochondria in order to increase the expression of the mtDNA-encoded genes, mitochondrial biogenesis, and oxidative phosphorylation. 81, 114 This leads to increased ATP and ROS production. It should be noted that the superoxide of ROS that is generated by the mitochondrial respiratory chain is normally detoxified by mitochondrial antioxidant systems, including manganese superoxide dismutase (MnSOD). As E2-ER also 
| Estrogen receptor-mediated nuclear signaling
The integration of ER signaling that is generated from various cellular locations appears to be critical in the regulation of cellular proliferation, differentiation, motility, and death, dependent on the estrogen target tissue. However, the nuclear ERs are clearly the dominant players in the manifestation of cellular responses to E2. The NLS that is located in the D region is required for the translocation of the ER to the nucleus. Although the mechanism by which the ER is translocated to the nucleus remains unclear, the import of nuclear hormone receptors to the nucleus is controlled by a multimeric chaperone machinery.
117
The interaction of NLS with importins and microtubule-associated molecular motor proteins appears to mediate NHR transport to the nucleus. 117 It also was reported that ERα contains a leucine-rich nuclear export sequence (NES) in the LBD. 118, 119 The NES, through binding to an exportin, was suggested to modulate the nucleocytoplasmic shuttling of ERα.
118,119
| Estrogen response element-dependent signaling pathway
The nuclear unliganded ERs are highly mobile molecules that are dynamically partitioned between target sites on chromatin and nuclear matrix. 51, 53 As mentioned, ERs mediate E2 action in the nucleus with two distinct modes: ERE-dependent and ERE-independent signaling pathways. In the ERE-dependent signaling route, ERs interact with a 5′-GGTCAnnnTGACC-3′ DNA palindrome sequence, the consensus ERE. Estrogen-responsive genes, however, contain single or multiple copies of EREs that deviate from the consensus by one or more nucleotides. 20, 48, 120 Although these EREs confer estrogen responsiveness that is mediated by the ER, they are less potent regulators of transcription than the consensus ERE. 20, 48, 120 The ERE binding of the E2-ERα complex is followed immediately by the recruitment of the Switch-Sucrose Non-fermentable chromatin remodeling complex that locks the nucleosomes into a stable orientation. This is followed by the recruitment of HMT and HATs to modify histones. The E2-ERα recruits members of the p160 co-activator family that includes SRC-1, transcription intermediary factor-2, and amplified in breast cancer-1. The AF-2 domain of ERα interacts with an amphipathic α-helix that contains the sequence LXXLL, in the so-called "nuclear receptor interacting domains" (NRIDs) of a cofactor. These NRIDs serve as signal input domains by anchoring the members of the p160 family co-activators to the promoter and connecting these proteins with the upstream end of the signaling pathway. The p160 family co-activators are also HATs that acetylate the chromosomal histone proteins. This results in destabilization of the histone-DNA contacts and chromatin decompaction in order to allow the positional phasing of the nucleosomes. These ERα-associated co-activators subsequently serve as a platform for the recruitment of p300, a co-integrator with HAT activity. The recruitment of p300 coincides with an increased level of histone acetylation and with the recruitment of the initiation-competent (unphosphorylated) form of RNA polymerase II and subsequent transcription initiation. Also, p300
appears to participate in the initiation of transcription. [122] [123] [124] [125] This recruitment of p300 is thought to catalyze chromatin modifications that prime the promoter for multiple rounds of transcription. [122] [123] [124] [125] The subsequent phosphorylation of the RNA polymerase II by a component of the basal transcription complex converts the polymerase to an elongation-competent form. [122] [123] [124] [125] Following these events, the dissociation of p300 from, and the subsequent binding of, cAMP response element-binding (CREB) protein and p300/CBP-associated factor (pCAF) to the complex take place. The CREB protein alone or together with pCAF further modifies chromatin through histone acetylation and/or methylation. These extensive alterations in the chromatin architecture provide the necessary scaffold for the ER complexes to enhance transcription through multiple rounds of transcription re-initiation. [126] [127] [128] [129] Studies also suggest that DNA methylation, particularly of CpG dinucleotides, occurs during the initial phase of every productive cycle and is associated with the recruitment of methyl CpG-binding protein 2 and DNA (cytosine-5-)-methyltransferase 1 to the promoter, which coincides with the recruitment of the remodeling complex, nucleosome remodeling deacetylase. [130] [131] [132] Moreover, E2-ERα-mediated restructuring and transcriptional competence of the responsive gene promoter appear to require the generation of a DNA double-stranded DNA break that is promoted by topoisomerase II. 133 Thus, ERα-mediated transcriptional events are tightly associated with induced local structural changes in chromatin. These changes encompass the positional phasing of nucleosomes and post-translational modification of nucleosomes, the methylation status of CpG dinucleotides, and the formation of DNA breaks. The
CREB protein also appears to be involved in the termination of transactivation by acetylating the acetyltransferases. The acetylation of the p160 proteins by the CREB protein leads to the disruption of the p160 co-regulator-receptor complex. [122] [123] [124] [125] This results in the termination of transcription and the remodeling of chromatin for recycling for transcription and/or proteasomal degradation. 134 Although the events that are associated with the initiation and termination of ERE-dependent genomic signaling could be similar between ERα and ERβ, the mode and extent of transcription that are mediated by the ERs through the ERE-dependent signaling pathway differ significantly. 135, 136 Comparative studies using heterologous reporter systems that emulate the ERE-dependent signaling pathway and endogenous ERE-driven gene responses 72, 78, 137, 138 indicate that ERβ, in response to E2, displays considerably less potency than ERα in inducing transcription in the ERE-dependent genomic signaling pathway.
Estrogen receptor α-AF-1, as discussed above, operates in cooperation with the carboxyl-terminus in a cell and promoter context-dependent manner. 48, 70, 139, 140 It appears that the ability of the A/B domain to recruit 72, 141, 142 and exchange 143 co-regulatory proteins is critical not only for AF-1, but also for the functional integration of both AF-1 and AF-2 of ERα to mediate transcription at full capacity in response to E2 in a tissue-specific manner. [70] [71] [72] 142 Consistent with these studies, mouse KI models suggest that, although AF-1 of ERα is dispensable for the vasculoprotective effects of E2, including the acceleration of the re-endothelialization process and the prevention of atheroma, both AF-1 and AF-2 of ERα are necessary for uterine physiology. 42, 43 In contrast to ERα, the amino-terminus of human ERβ impairs the receptor-ERE interactions, 77 lacks an activation function, 19, 72, [78] [79] [80] and is incapable of interacting with the carboxyl-terminus. 72 Therefore, this indicates that the distinct amino-termini of ERs define the differences in the magnitude of transcriptional responses that are mediated through the ERE-dependent E2-ER signaling pathway. Nevertheless, the ability of ERβ to bind to an ERE with a lower affinity than ERα 48, 144 and to interact with a different set of proteins 48, 145 also contributes to distinct ER actions in the ERE-dependent signaling pathway.
| Estrogen response element-independent signaling pathway
The ability of E2-ER to mediate gene expression by functional interactions with, for example AP-1 and Sp-1, transcription factors bound to their cognate element on DNA, constitutes the ERE-independent signaling pathway. 19, [56] [57] [58] [59] [60] This pathway is dependent on the receptor subtype, nature of the ER ligand, and the cell context. co-regulators, as exemplified with the p160 proteins and CREB protein, 60, 150, 151 in transcription at the ERE and TRE sites, the different combinatorial assembly of co-regulatory proteins appears to be critical for ERα-mediated signaling events through the TRE-dependent pathway. Indeed, the observations that SERMs and SERDs can activate, rather than repress, the transcriptional responses that are mediated by ERα, but not ERβ, at a TRE site 60, 150, 151 suggest that the altered pharmacology of ER ligands could be explained by differences in the amount and/or type of the co-regulatory proteins, which show variations in cells from different tissues of origin. 152 Moreover, ERα, but not ERβ, in response to E2 cross-talks with the SP-1 transcription factor to modulate the transcription of a variety of estrogen-responsive genes. 58, 153, 154 This interaction is mediated by the tethering of ERα to the GC box response element-bound SP-1 protein. 58, 153, 154 Moreover, it appears that the amino-terminal of region ERα is critical for responses from GC box element-bearing promoters. 58, 153, 154 In cellula and in vivo studies have attempted to understand the importance of the ERE-independent pathway in E2-ER signaling by dissecting nuclear ER signaling pathways. Studies, as discussed, indicated that Glu203, Gly204, and Ala207 residues, of the P-box in the DNA-binding helix of human ERα, determine the DNA-binding specificity that is critical for sequence discrimination 12, 62, 63 and binding to ERE. 64 Changing Glu203 and Gly204 residues to Ala in the DNA-binding helix of the human 155 and the corresponding residues of the mouse 149 ERα generates a mutant receptor that is capable of mediating E2 signaling only through the ERE-independent pathway.
Analogous mutations in the DBD of the human ERβ 59,156 also render the receptor functional only in the ERE-independent signaling pathway. Studies with a mouse KI model of the P-box in the DNAbinding helix of mouse ERα (ERα AA ) provide compelling support for the importance of the ERE-independent pathway in the regulation of various tissue functions, albeit in a tissue-specific manner.
157-159
On the other hand, in an attempt to correlate the genomic responses from the ERE-independent signaling pathway to alterations in cellular phenotypes, the authors found that changing Glu203Ala and Gly204Ala human ERα reduces, but does not prevent, the functional features of ERα in the ERE-dependent signaling pathway. 64 Moreover, Glu203Ala and Gly204Ala mutations could alter the response element specificity of ERα, as indicated by studies using ERα AA mouse uteri, which showed that the ERα AA mutant binds to hormone-responsive motifs that are normally occupied by the progesterone receptor, leading to E2 regulation of uterine transcripts that are normally progesterone-responsive. 160 Previous studies indicated that a network of protein-DNA hydrogen bonds confers the binding specificity and stability of the human ERα to DNA. 61, 161 For the consensus ERE, the network involves residues Glu203, Lys207, Lys210, and Arg211. 161 Although the recognition of a non-consensus ERE is achieved by a rearrangement of the side chains of various residues of ERα-DBD, particularly Lys207 and Lys210, the interactions of Glu203 and Arg211 with DNA remain unaltered. 161 Based on these observations, the replacement of positively charged Arg211, which is a conserved residue among NHRs, with the negatively charged Glu residue in the ERα203/204 mutant generated an ERE-binding defective ERα mutant (or ERα EBD ) that abolished the in vitro and in cellula ability of ERα EBD to interact with and to modulate transcription from an ERE while retaining the functionality at simulated ERE-independent signaling pathways in various cell lines. 64 Furthermore, the ERα EBD in response to E2 mediated a subset of estrogen-responsive genes in a manner that was similar to E2-ERα, but it was insufficient to alter the phenotypic features of the cell models, in contrast to E2-ERα. 64 Identical results were observed with an EREbinding mutant of ERβ. 156 This suggests that the genomic responses from the ERE-independent signaling pathway can be dissociated from the induction of phenotypic alterations. These findings also imply that the ERE-dependent pathway is a required signaling route for E2-ERs to induce cellular responses. This conclusion is supported by the observations that were derived from a mutant KI mouse (ERα EAAE ) model bearing mutations at the DBD that synthesize an ERE-binding defective ERα mutant that is incapable of modulating transcription from the ERE-dependent signaling pathway but that is effectively regulating gene expression at the ERE-independent signaling route. 162 
| INCREASING THE REPERTOIRE OF ESTROGEN RECEPTOR ACTIONS
| Estrogen receptorαβ heterodimer
Due to the shared and distinct regulatory potentials of ERα and ERβ, the repertoire of ER activity in response to E2 is expected to expand through the heterodimerization of ERs in cells that synthesize both subtypes. Early studies showed that ERα and ERβ, when 
| Estrogen receptor variants
Alterations in the expression of ER subtypes by epigenetic events, as well as by the generation of ER-variant proteins through alternative splicing, are important elements that alter the dynamic regulation of tissue functions and also contribute to the initiation and/or the development of malignancies (Fig. 2) .
Seven different promoters that are located upstream of the first coding exon are involved in the transcription of the ERα gene. [14] [15] [16] The detection of distinct ERα transcripts in different tissues suggests that the composition of regulatory promoter elements is critical for The promoter regions of the ERs are also GC-rich, implying a susceptibility to change in methylation status, an event that is associated with altered gene expression and an increased risk of disease. stitutive activity in some breast cancer cell lines. [190] [191] [192] [193] Likewise, the splice variant of exon 7 expresses an ERα in the normal breast tissue that lacks both transactivation and hormone-binding functions. This variant binds to DNA and behaves like a dominant negative isoform for both ERα and ERβ and thus regulates estrogen responsiveness. 190, 193 Evidence for the existence of endogenous ERα variant proteins, on the other hand, is limited to a few. For example, an ERα variant with a MM of 46 kDa (ERα46) is found to be present in human primary osteoblasts, 194 an analog of which is also present in the bone of the original ERα-KO mice model. 194, 195 This isoform, expressed at a level similar to WT-ERα, is generated by an alternative splicing of the ERα gene, which results in exon 1 being skipped, with a start codon in exon 2 being used to initiate translation of the protein. Consequently, the AF-1 of this ERα isoform is absent. Functional analyses suggest that this amino-terminally truncated ERα is able to heterodimerize with WT-ERα and also with WT-ERβ. ERα46 is a strong inhibitor of WT-ERα when co-synthesized and represses cellular proliferation in response to E2. 194, 195 ERα36 is generated from a promoter in the first intron of the ERα gene and continues from exon 2 to exon 6 and skips exons 7 and 8. 196,197 This results in a unique carboxyl-terminus of 27 amino acids that replaces the last 138 amino acids of full-length ERα. 196, 197 ERα36 is localized mainly in the cytoplasm and the plasma membrane.
Palmitoylation of ERα36 could contribute to the membrane localization of the variant. It appears that ERα36 mediates membrane-initiated E2 signaling and adversely affects the events that are mediated by both ERα and ERβ. 196, 197 Multiple ERβ transcripts exist as a result of the alternative usage of untranslated exons in the 5′ of the gene, alternative splicing of the last coding exons, or deletion of one or more coding exons. For example, although very rare among the population, 198 an ERβ testis cDNA that encodes an amino-terminally extended ERβ isoform was reported. 199 This variant ERβ results from the presence of an additional A-T base pair in the 5′-untranslated region of the ERβ gene that generates an early ATG initiation codon that extends the aminoterminus of ERβ by 18 additional amino acids; hence, it is referred to as "ERβ548." 199 Interestingly, ERβ548 displays a more robust activity than WT-ERβ in inducing transcription in an ERE-dependent reporter system. Moreover, tamoxifen and raloxifene appear to act as agonists for ERβ548, in contrast with their action as antagonists for WT-ERβ. 199 In addition, many ERβ variants that have resulted from alternative splicing events also have been reported in normal and pathological estrogen target tissues. Although the importance of these ERβ splice variants remains unclear, several major variants have been described to alter E2-ER signaling in experimental systems. [200] [201] [202] [203] Of these, ERβ2, 4, and 5, which contain exons 1-7 of the human ERβ gene, followed by alternatively spliced exon 8, have been studied in detail. The studies indicate that although these carboxyl-terminally truncated variants cannot bind ligand and lack co-activator-recruiting helix 12, they can heterodimerize with WT-ERβ, as well as with WT-ERα, and modulate estrogen-mediated transcriptional activities of the receptors, raising the possibility that when co-synthesized, ERβ isoforms could adversely alter ERα and ERβ signaling.
200-203
| EPILOGUE
Despite a large number of experimental studies indicating that ERα and ERβ show similar, as well as distinct, regulatory potentials in cells of different estrogen target tissues, the physiological role of ERβ in E2-mediated signaling remains elusive. However, one consensus is that rather the subtype, the relative level of synthesis of ERs and ER variants, particularly in cases wherein both subtypes are synthesized, can have profound effects on the dynamic and integrated network of cellular events in both the physiology and pathophysiology of target tissues. Although beyond the scope of this paper, and there are many excellent reviews, [204] [205] [206] [207] [208] [209] [210] one important integrated network involves the cross-talk of E2-ER with growth factor signaling pathways (GFSPs). These GFSPs modify, and are modified by, E2-ER signaling. 201, 202 Adding further complexity to E2-ER signaling, are phosphorylation, glycosylation, ubiquitination, and acetylation events that not only modulate unliganded or liganded ER functions at every level but also alter the ligand pharmacology. [204] [205] [206] [207] [208] [209] [210] The deregulation of growth factor signaling appears to play a vital role in ER-driven neoplastic processes and also the development of endocrine resistance in the treatment of estrogen target tissue malignancies, exemplified by breast cancers. [204] [205] [206] [207] [208] [209] [210] Consequently, a better understanding of the complex regulatory mechanisms that underlie ER actions holds considerable promise for the development of novel biomarkers and predictors, as well as therapeutic approaches that could have a substantial impact on the systemic management of estrogen target tissue malignancies.
